EGFR and breast carcinoma: (1)GPX4 degradation enhances ferroptosis-induced anti-tumor immunity in pancreatic cancer [153].(2)Suppressing de novo glutathione synthesis overcomes acquired resistance to EGFR-targeted therapy in lung cancer [154].(3)GPX4 prevents ferroptosis and contributes to tamoxifen resistance in breast cancer [155].(4)Induction of ferroptosis and inhibition of glutathione is a therapeutic approach in prostate cancer [156].